Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2020-06-24 Share Issue/Capital Cha…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA - Contemplated Private Placement
Share Issue/Capital Change Classification · 99% confidence The document is titled "Photocure ASA - Contemplated Private Placement" and details the intent to issue new shares (Offer Shares) to raise capital through an accelerated bookbuilding process managed by Joint Bookrunners. This activity—raising capital through the issuance of new shares—directly corresponds to the definition of a Capital/Financing Update (CAP). Although it involves shares, it is a financing event rather than a general share issue announcement (SHA) or a transaction in own shares (POS), as the primary focus is the fundraising mechanism (Private Placement). It is a primary announcement of a financing activity, not a report itself, thus ruling out RPA/RNS based on the content type.
2020-06-24 English
Photocure ASA - Contemplated Private Placement
Capital/Financing Update Classification · 98% confidence The document is titled 'Photocure ASA - Contemplated Private Placement' and details the plan to issue up to 2,500,000 new shares through a private placement to raise capital. It discusses the use of proceeds, the bookbuilding process, and the involvement of investment banks (Managers). This activity directly relates to fundraising, financing activities, and changes in the capital structure. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it describes a specific corporate financing event.
2020-06-24 English
Photocure Enters into Final Agreement to Regain Worldwide Rights of Hexvix
Regulatory Filings Classification · 95% confidence The document is a press release dated June 11, 2020, announcing that Photocure has entered into a final agreement with Ipsen to regain worldwide rights for Hexvix®. It details the financial terms of the transfer, future revenue targets, and strategic outlook. This type of announcement, which details a significant corporate transaction (regaining commercial rights) and provides financial projections, is characteristic of a major corporate event disclosure. It is not a formal regulatory filing like a 10-K or an IR, nor is it a transcript or a simple dividend notice. Since it announces a major business development and provides financial context, it fits best under Capital/Financing Update (CAP) if the focus is on the transaction structure, or potentially a Regulatory Filing (RNS) if it's a general market disclosure required by the Oslo Stock Exchange (OSE). Given the focus on regaining rights and the associated payment structure (EUR 15 million payment, earn-outs), it strongly relates to capital structure/financing activities or a major corporate transaction. However, none of the specific codes perfectly capture a 'Major Business/M&A Announcement' outside of TAR (M&A Activity), which usually implies a takeover bid or merger proposal. Since this is about regaining rights and includes financial targets, it is a significant corporate disclosure. In the context of the provided definitions, it is a significant corporate event announcement. It is not a standard Earnings Release (ER) or Interim Report (IR). Because it details a major transaction involving financing and asset acquisition, 'Capital/Financing Update' (CAP) is a plausible fit, but 'Regulatory Filings' (RNS) is often used for press releases detailing such material non-public information required by the exchange, especially when a specific M&A code (TAR) doesn't perfectly align with a rights reversion. Given the nature of the announcement (a major agreement impacting future revenue and operations), it is most likely a required regulatory disclosure that doesn't fit the other specific categories, making RNS the safest general classification for a material press release, or CAP due to the financial implications. I will lean towards RNS as the most appropriate catch-all for a material press release that isn't explicitly an ER, IR, or a specific proxy/dividend notice, although it has strong elements of CAP.
2020-06-11 English
Photocure Enters into Final Agreement to Regain Worldwide Rights of Hexvix
Regulatory Filings Classification · 90% confidence The document is a press release dated June 11, 2020, announcing that Photocure has entered into a final agreement with Ipsen to regain worldwide commercial rights for Hexvix. It details the financial terms (payment, earn-outs), strategic implications, and future revenue targets. This type of announcement, which details a significant corporate transaction (M&A/licensing agreement) and its financial impact, is best classified as a general corporate announcement. Since there is no specific category for 'M&A Activity' that covers licensing buybacks, and it is not a standard regulatory filing like 10-K or ER, it falls under the general regulatory announcement category, RNS, as it is a material event disclosed to the market (OSE notification reference is made). However, given the focus on a major transaction involving the acquisition/regaining of commercial rights, 'TAR' (M&A Activity) is a strong candidate, but TAR is usually reserved for takeover bids or mergers. Since this is a significant corporate transaction announcement, and it is not a standard financial report, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate fallback for a material, non-standard report announcement, or 'CAP' (Capital/Financing Update) if the focus was purely on the financing aspect, but the core is the rights transfer. Given the context of a major commercial agreement, and lacking a specific 'Licensing/Asset Acquisition' code, RNS is the safest general classification for a material press release.
2020-06-11 English
Photocure ASA - Annual general meeting held
AGM Information Classification · 99% confidence The document text explicitly contains the title 'PROTOKOLL FRA ORDINÆR GENERALFORSAMLING' and 'MINUTES FROM ANNUAL GENERAL MEETING' for 'PHOTOCURE ASA'. It details the proceedings, agenda items (like opening, election of chairperson, approval of annual accounts, and remuneration vote), and resolutions passed during this meeting. This content directly corresponds to the definition of AGM Information.
2020-06-10 English
Photocure ASA - Annual general meeting held
AGM Information Classification · 98% confidence The document explicitly states that the 'Annual general meeting' was held on June 10, 2020, and confirms that 'All proposals were resolved as presented'. It references the minutes of the meeting being attached. This content directly relates to the proceedings and outcomes of the Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document is short and reports the outcome, not just announcing the publication of a separate report.
2020-06-10 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.